Endoscopy & Visualization in Massachusetts

Revvity, Inc. is a comprehensive life science solutions provider serving academia, pharmaceutical, biotech, clinical laboratories, contract research organizations, and healthcare professionals globally. The company operates across the drug discovery-to-diagnostics continuum, delivering integrated workflows in translational multi-omics, biomarker identification, imaging, screening, detection, diagnosis, and informatics. Product portfolio includes high-content screening instruments (Opera Phenix, EnVision plate readers), optical imaging systems (IVIS), cell analysis instruments (Cellometer), sample preparation equipment (Omni Bead Ruptor Elite homogenizers), and laboratory automation (Fontus workstations, LabChip systems). Reagent brands encompass BioLegend antibodies and flow cytometry reagents, AlphaLISA and SureFire immunoassays, HTRF TR-FRET assays, Dharmacon RNAi and CRISPR tools, and custom oligonucleotide synthesis. Representative diagnostic and clinical service offerings include newborn screening (33M+ annual screens), immunodiagnostics via EUROIMMUN solutions (85M+ blood samples analyzed), infectious disease serology, TB testing (T-SPOT.TB, 20M+ tested since 2002), reproductive health solutions (maternal/prenatal testing, cell-free DNA analysis, preeclampsia management), and clinical genomics services (300M+ tests performed). Licensing portfolio covers gene expression, editing, and viral vector technologies including LentiBOOST and Pin-point base editing platforms. Revvity serves 94% of top 50 global pharma companies, maintains ~11,000 employees worldwide, and operates on-site manufacturing, viral vector engineering, preclinical oncology services, and clinical testing. Regulatory presence includes FDA and CE approvals across diagnostics and instruments. The company integrates acquisition-driven growth with organic R&D, supporting discovery through clinical deployment across life science workflows.

Rebion, Inc. commercializes Neural Performance Scanning (NPS), a proprietary technology platform that measures neurophysiologic mechanisms of the optic nerve/brain continuum through retinal scanning. The company's primary product, Blinq®, is an FDA-cleared portable point-of-care neural performance scanner designed for pediatric vision screening. Blinq directly detects micro-strabismus and amblyopia (lazy eye) by quantifying bilateral fixation and saccadic eye movements, achieving up to 100% sensitivity and over 90% specificity in clinical evaluations. The device performs a 3-second neural performance scan capable of detecting binocularity impairments associated with as little as 1-degree misalignment. Rebion's technology is supported by peer-reviewed clinical studies and research conducted at major medical institutions. The company also develops Traq™, an investigational device leveraging NPS to measure visual tracking impairments for clinical research purposes (currently not available for sale in the United States). Rebion serves diverse markets including community screeners, schools and administrators, clinical staff, parents, and caregivers. The platform enables early disease detection, intervention, and customized treatment across clinics, schools, and public health initiatives, reducing unnecessary referrals while improving diagnostic accuracy and patient outcomes.

DeepHealth is a global leader in AI-powered health informatics and radiology solutions, headquartered in Somerville, Massachusetts and operating as a subsidiary of RadNet, Inc. Founded in 2015, the company develops cloud-native platforms that integrate diagnostic imaging tools with advanced artificial intelligence to enhance clinical workflows and patient outcomes. DeepHealth OS, the company's core cloud-native operating system, unifies enterprise data and provides AI-driven insights tailored for radiologists and care teams. The platform supports detection, assessment, and monitoring across multiple imaging modalities. Key clinical AI solutions include breast cancer screening (Breast Suite with ProFound Pro and Safeguard Review), lung cancer management, prostate health, and brain health diagnostics. DeepHealth's remote scanning capability (TechLive™) enables multimodality, vendor-agnostic imaging delivery. The company serves over 300 screening sites globally and processes more than 15 million annual exams across the U.S. and Europe. Recent strategic acquisitions of Gleamer, CIMAR UK, and Alpha RT assets have expanded DeepHealth's portfolio in clinical AI, image management, and remote staffing services.

Heidelberg Engineering GmbH is a global leader in ophthalmic imaging and data solutions, founded in 1990 and trusted by eye care professionals in over 120 countries. The company specializes in high-precision diagnostic imaging systems for anterior and posterior segment ophthalmology, coupled with integrated healthcare IT solutions optimized for eye care workflows. Core product portfolio includes SPECTRALIS (multimodal retinal imaging platform), ANTERION (anterior segment imaging platform), Heidelberg Eye Explorer (ophthalmology-specific healthcare IT), and a fully digital surgical visualization platform. These solutions enable early disease detection, visualization of subtle retinal and anterior segment changes, treatment guidance, and reproducible high-definition imaging with seamless clinical infrastructure integration. The company operates a robust global support infrastructure with multilingual service capabilities and distributes products across diverse markets including academic medical centers, private practices, and research institutions. Heidelberg Engineering operates the Heidelberg Engineering Academy, providing over 20 years of continuous clinical education, hands-on training, and on-demand learning resources for eye care professionals worldwide. The company demonstrates strong commitment to scientific innovation through collaboration with leading research institutions and participation in major ophthalmic symposia (ISS, ARVO). Manufacturing and regulatory certifications align with medical device standards for ophthalmology markets.

PaxeraHealth is a Boston-based enterprise medical imaging software company specializing in AI-driven imaging platforms and solutions. The company develops advanced Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and vendor-neutral archive (VNA) platforms designed for healthcare providers globally. PaxeraHealth's core portfolio includes PaxeraUltimaAI—an AI-assisted enterprise imaging platform with native diagnostic algorithms to enhance workflow efficiency and reporting speed; ARK—a no-code imaging algorithm platform enabling users to develop multimodal AI algorithms without coding expertise; and VNAi—a data warehouse imaging platform providing secure, vendor-neutral control of imaging data with advanced lifecycle management. The company serves over 1,500 healthcare customers across 45 countries, managing 220+ million imaging studies annually. PaxeraHealth's solutions emphasize workflow automation, diagnostic accuracy improvement, clinical decision support, and seamless interoperability with existing EMR and PACS systems. The company employs approximately 106 people from 12 countries and maintains regional offices and a global distributor network to support healthcare systems of all sizes.

Phelcom Technologies is a medical device manufacturer specializing in portable ophthalmic imaging solutions. The company designs and produces the Eyer and Eyer2 portable fundus cameras—high-quality, portable retinal imaging devices capable of capturing fundus images with 55 degrees of visual field and anterior segment photography. Eyer2 represents their latest iteration, marketed as the world's first high-quality portable fundus camera. The company operates a cloud-based image management platform, EyerCloud, enabling automatic and secure exam storage and accessibility. Phelcom's devices are positioned for use in diverse clinical settings including private optometry practices, ophthalmology clinics, pediatric care, and remote/resource-limited environments. The Eyer devices have been featured in peer-reviewed research and are approved by regulatory bodies including ANVISA (Brazilian health authority, Class II medical device) and cleared for use in multiple countries. The company provides training and support services for end users and maintains a US headquarters in Cambridge, Massachusetts. Customer testimonials emphasize ease of use, image quality, portability, and utility for patient education and anterior segment documentation. Phelcom has received investment backing from established healthcare and life science funds, signaling credibility in the medical device space.